Collecting Cancer Data: Uterus

2014-2015 NAACCR Webinar Series February 5, 2015

NAACCR

Q&A


Please submit all questions concerning webinar content through the Q&A panel.

Reminder:

• If you have participants watching this webinar at your site, please collect their names and emails.

 We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.






KEY FACTS-PROJECTIONS


- Uterine Cervix
- New cases: 12,900
- Deaths: 4,100
- Uterine Corpus
- New cases: 54,870
- Deaths: 10,170
 - Cancer Facts & Figures 2015


NAACCR

HUMAN PAPILLOMA VIRUS (HPV) INFECTION


- Epidemiologic studies convincingly demonstrate that the major risk factor for development of preinvasive or invasive carcinoma of the cervix is HPV infection
- About two-thirds of all cervical cancers are caused by HPV 16 and 18
- $\boldsymbol{\cdot}$ Infection with HPV is common
- \bullet Pap tests look for changes in cervical cell caused by HPV infection








NAACCR 2014-2015 Webinar Series





CARCINOMA IN SITU OF THE CERVIX, CIN, AND THE BETHESDA SYSTEM

- In 1993 a NAACCR multidisciplinary group recommended that until
- There is a strong local interest
- Sufficient resources are available to collect all high grade squamous intraepithelial lesions That population based registries discontinue
- collection • NAACCR and NPCR adopted this
- recommendation at that time.
- SEER and CoC adopted it effective for 1/1/1996.




NAACCR 2014-2015 Webinar Series

HISTOLOGY-CERVIX

- Columnar Epithelium
 Adenocarcinoma
- Squamous Epithelium
 Squamous cell carcinoma
- Squamo-columnar
- junction
- OriginalNew
- New

NAACCR



CERVICAL ECTROPION

 The central (endocervical) columnar epithelium protrudes out through the external os of the cervix and onto the vaginal portion of the cervix



10%

4%

1% 10%

 Undergoes squamous metaplasia, and transforms to stratified squamous epithelium.

NAACCR

HISTOLOGY- ENDOMETRIUM

Adenocarcinoma of the endometrium

- Type 1
- Endometrioid adenocarcinoma grades 1&2
 75-80%
- Type 2
- Endometriod adenocarcinoma grade 3
- Papillary serous carcinoma
- Clear cell carcinomaMucinous carcinoma
- Mixed

Required Histology	Combined Histology	Combination Term	Code
Gyn malignancies with two or more of the histologies in column 2	Clear Cell	Mixed cell	8323/3
	Endometrioid	adenocarcinoma	
	Mucinous		
	Papillary		
	Serous		
	Squamous		
	Transitional	1	

EXAMPLE

- A single tumor of the endometrium:
 Endometrioid with clear cell differentiation.
- Rule H16 refers us to Table 2
- Mixed cell adenocarcinoma 8323/3


HISTOLOGY

Carcinosarcoma (CS Schema Corpus Carcinoma)
 Mixed Mullerian


Slide Changed


- Leiomyosarcoma (CS Schema Corpus Sarcoma)
 Rhabdomyosarcoma
- Endometrial stromal sarcoma (CS Corpus Schema Sarcoma)
- Adenosarcoma (CS Schema Corpus Adenosarcoma)

NAACCR















CERVIX UTERI: CHAPTER 35

NAACCR

AJCC CANCER STAGE: CERVIX UTERI

• ICD-O-3 Topography Codes • C53.0, C53.1, C53.8, C53.9

- ICD-O-3 Histology Code Ranges
- 8000-8576
- 8940-8950
- 8980-8981

AJCC CANCER STAGE: CERVIX UTERI CLASSIFICATION

- Clinical Staging
- FIGO uses clinical staging
- Determined prior to start of definitive therapy
- Clinical examination
- Palpation, inspection, colposcopy, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and x-ray of lungs and skeleton
- Lymph node status
- Radiologic-guided fine needle aspiration, laparoscopic or peritoneal biopsy, or lymphadenectomy

NAACCR

AJCC CANCER STAGE: CERVIX UTERI CLASSIFICATION

- Clinical Staging
- CT, MRI, PET
- Ignore for staging
- May be used to make treatment plan

VAACCR

AJCC CANCER STAGE: CERVIX UTERI CLASSIFICATION

Pathologic Staging

- Based on information acquired before treatment and supplemented by additional evidence from surgery, particularly from pathologic exam of resected tissues
- Does not change clinical staging

VAACCR

AJCC CANCER STAGE: CERVIX UTERI T CATEGORY

TNM	FIGO	Description
TΧ		Primary tumor cannot be assessed
TO		No evidence of primary tumor
Tis		Carcinoma in situ

TNM	FIGO	Description
T1	I	Confined to uterus (extension to corpus should be disregarded)
T1a	IA	Invasive carcinoma diagnosed only by microscopy; maximum depth of stromal invasion 5 mm & horizontal spread 7 mm or less
T1a1	IA1	Stromal invasion 3 mm or less in depth & 7 mm or less horizontal spread
T1a2	IA2	Stromal invasion more than 3 mm & not more than 5 mm with 7 mm or less horizontal spread

TNM	FIGO	Description
T1	I	Confined to uterus (extension to corpus should be disregarded)
T1b	IB	Clinically visible lesion confined to cervix or microscopic lesion greater than T1a/IA2
T1b1	IB1	Clinically visible lesion 4 cm or less in greatest dimension
T1b2	IB2	Clinically visible lesion more than 4 cm in greatest dimension

TNM FIGO Description		
INIVI	FIGO	Description
T2	11	Invades beyond uterus but not to pelvic wall or lower third of vagina
T2a	IIA	Without parametrial invasion
T2a1	IIA1	Clinically visible lesion 4 cm or less in greatest dimension
T2a2	IIA2	Clinically visible lesion more than 4 cm in greatest dimension
T2b	IIB	Tumor with parametrial invasion

TNM	FIGO	Description
T3	III	Extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non- functioning kidney
T3a	IIIA	Involves lower third of vagina, no extension to pelvic wall
T3b	IIIB	Extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney
T4	IVA	Invades mucosa of bladder or rectum and/or extends beyond true pelvis

NM	FIGO	Description
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1	IIIB	Regional lymph node metastasis

AJCC CANCER STAGE: CERVIX UTERI M CATEGORY

	HGO	Description
M0		No distant metastasis

M1 IVB Distant metastasis

Group	T	N	М
Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage IA	T1a	N0	M0
Stage IA1	T1a1	N0	M0
Stage IA2	T1a2	N0	M0
Stage IB	T1b	N0	M0
Stage IB1	T1b1	N0	M0
Stage IB2	T1b2	NO	MO

Group	Т	N	М
Stage II	T2	NO	MO
Stage IIA	T2a	NO	M0
Stage IIA1	T2a1	NO	M0
Stage IIA2	T2a2	N0	M0
Stage IIB	T2b	NO	MO

Group	T	N	М	
Stage III	T3	N0	M0	
Stage IIIA	T3a	N0	M0	
Stage IIIB	T3b T1-3	Any N N1	M0 M0	
Stage IVA	T4	Any N	M0	
Stage IVB	Any T	Any N	M1	

NAACCR

POP QUIZ

- Clinical exam & colposcopy: Visible lesion of cervix, 2.5 cm; no lymphadenopathy.
- Chest x-ray: Normal.
- Curettage and cervical biopsy: Moderately differentiated squamous cell carcinoma of cervix with 1.5 mm depth of stromal invasion.
- Radical hysterectomy operative report: 2.5cm cervical tumor confined to cervix.
- Pathology report: 2.3 cm moderately differentiated squamous cell carcinoma with a depth of invasion of 6.0 mm.

VAACCR

POP QUIZ

- What is the AJCC clinical stage?
- $\boldsymbol{\cdot}$ What is the AJCC pathologic stage

Summary Stage 2000 http://seer.cancer.gov/tools/ssm/

CERVIX UTERI

VAACCR

SUMMARY STAGE 2000: CERVIX UTERI

• 0 In situ

- Noninvasive; intraepithelial
- Preinvasive
- $\boldsymbol{\cdot}$ Cancer in situ WITH endocervical gland involvement
- CIN (cervical intraepithelial neoplasia) grade III

NAACCR

SUMMARY STAGE 2000: CERVIX UTERI

1 Localized only

Invasive cancer confined to cervix uteri

- Minimal microscopic stromal invasion \leq 3 mm in depth and \leq 7 mm in horizontal spread

- FIGO Stage IA1
- Microinvasion; Tumor WITH invasive component > 3 mm and \leq 5 mm in depth, taken from the base of the epithelium, and \leq 7 mm in horizontal spread
- FIGO Stage IA2

SUMMARY STAGE 2000: CERVIX UTERI

1 Localized only

- Invasive cancer confined to cervix uteri
- Invasive cancer confined to cervix and tumor > 5 mm in depth and/or > 7 mm in horizontal spread
- FIGO Stage IB

• FIGO Stage I not further specified

- Localized NOS:
- Confined to cervix uteri
- Confined to uterus NOS (except corpus uteri NOS)

SUMMARY STAGE 2000: CERVIX UTERI

- 2 Regional by direct extension only
 Extension to/involvement of: Corpus uteri, cul de sac (rectouterine pouch), upper 2/3 of vagina including fornices, vagina NOS, vaginal wall NOS
 FIGO Stage IIA
- Extension to:
- Ligament(s): Broad, cardinal, uterosacral
- Parametrium (paracervical soft tissue)

FIGO Stage IIB

NAACCR

NAACCR

SUMMARY STAGE 2000: CERVIX UTERI

- 2 Regional by direct extension only
 Extension to: Bladder NOS excluding mucosa, bladder wall, lower 1/3 of vagina, rectal wall NOS, rectum NOS excluding mucosa, ureter intra- and extramural, vulva
- Bullous edema of bladder mucosa
- FIGO Stage IIIA

SUMMARY STAGE 2000: CERVIX UTERI

- 2 Regional by direct extension only
 Extension to: Fallopian tube(s), ovary(ies), pelvic wall(s), urethra
- FIGO Stage IIIB
- Tumor causes hydronephrosis or nonfunctioning
- kidney FIGO Stage IIIB
- FIGO Stage III NOS

NAACCR

SUMMARY STAGE 2000: CERVIX UTERI

- 3 Regional lymph node(s) involved only
- Iliac NOS: Common; external; internal (hypogastric) NOS - obturator
- Paracervical
- Parametrial
- Pelvic NOS
- · Sacral NOS: Lateral (laterosacral); middle (promontorial) (Gerota's node); presacral; uterosacral

Regional lymph node(s) NOS

VAACCR'

SUMMARY STAGE 2000: CERVIX UTERI

- 4 Regional by BOTH direct extension AND regional lymph node(s) involved • Codes (2) + (3)
- 5 Regional NOS
- FIGO Stage III NOS

SUMMARY STAGE 2000: CERVIX UTERI

- 7 Distant site(s)/node(s) involved
- Distant lymph node(s):
 Aortic, NOS: Lateral (lumbar), para-aortic, periaortic

- Inguinal
 Mediastinal
 Other distant lymph node(s)
- Extension to: Bladder mucosa (excluding bullous edema); rectal mucosa
- Further contiguous extension beyond true pelvis: Sigmoid colon; small intestine
- MetastasisFIGO Stage IV, IVA, IVB

VAACCR

POP QUIZ

- Clinical exam & colposcopy: Visible lesion of cervix, 2.5 cm; no lymphadenopathy.
- · Chest x-ray: Normal.
- Curettage and cervical biopsy: Moderately differentiated squamous cell carcinoma of cervix with 1.5 mm depth of stromal invasion.
- Radical hysterectomy operative report: 2.5cm cervical tumor confined to cervix.
- Pathology report: 2.3 cm cervical lesion, moderately differentiated squamous cell carcinoma, with a depth of invasion of 6.0 mm.

VAACCR'

POP QUIZ

- What is the code for Summary Stage 2000?
- a. 0 In situ
- b. 1 Localized only
- c. 2 Regional by direct extension only
- a. Regional by direct extension only
 d. 3 Regional lymph node(s) involved only
 e. 4 Regional by BOTH direct extension AND regional lymph node(s) involved
 f. 5 Regional NOS
 a. 7 Distant site (s) (see the (see the second seco
- 7 Distant site(s)/node(s) involved g. h. 9 Unknown if extension or metastasis

Collaborative Stage Data Collection System (CS) V0205

CERVIX UTERI

VAACCR

VAACCR'

CS: CERVIX UTERI

CS Tumor Size

- Code the largest measurement of horizontal spread or surface diameter
- CS Extension
- T category is based on CS Tumor Size for CS Extension codes 200-310, 380-450, and 550 ONLY
 Derives T1b1, T1b2, T1bNOS, T1NOS, T2a1, T2a2, T2aNOS, T2NOS

SSF1: CERVIX UTERI

- FIGO stage
- Code as documented in medical record
- Do not try to code from T, N, M values
- Assign code 987 for carcinoma in situ or CIN III
- CS Extension = 000 or 010
- FIGO Stage does not include Stage 0 (in situ) for cervix uteri
- Assign code 999 if FIGO stage is unknown or not documented

Corpus Uteri: Chapter 36

AJCC CANCER STAGE: CORPUS UTERI

- ICD-O-3 Topography Codes • C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55.9
- ICD-O-3 Histology Code Ranges
- 8000-8576
- 8890-8898
- 8930-8933
- 8940-8950
- 8980-8981

NAACCR

NAACCR

AJCC CANCER STAGE: CORPUS UTERI

- 2 separate staging schemas
- Uterine carcinomas
- Includes carcinosarcoma
- Uterine sarcomas
- Leiomyosarcoma & endometrial stromal sarcoma
 Adenosarcoma

AJCC CANCER STAGE: CORPUS UTERI **CLASSIFICATION**

Clinical Staging
 Based on evidence acquired before initiation of treatment


- Pathologic Staging
 FIGO uses surgical/pathologic staging
 Based on information acquired before treatment supplemented by information acquired from pathologic assessment of resected tissues
 Record depth of myometrial invasion with thickness of myometrium
- Assess regional lymph nodes surgically/pathologically

TNM	FIGO	Description
ΤX		Primary tumor cannot be assessed
TO		No evidence of primary tumor
Tis		Carcinoma in situ
T1	I	Confined to corpus uteri
T1a	IA	Limited to endometrium or invades less than ½ of myometrium
T1b	IB	Invades ½ or more of myometrium

TNM	FIGO	Description
T2	II	Invades stromal connective tissue of cervix but does not extend beyond uterus
T3a	IIIA	Involves serosa and or adnexa (direct extension or metastasis)
T3b	IIIB	Involves vagina (direct extension or metastasis) or parametrium
T4	IV	Invades bladder mucosa and/or bowel mucosa

N CATEGORY UTERINE CARCINOMA

NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1	IIIC1	Regional lymph node metastasis to pelvic nodes
N2	IIIC2	Regional lymph node metastasis to para-aortic nodes with or without positive pelvic nodes



Group	T	N	М
Stage 0	Tis	NO	M0
itage I	T1	NO	M0
itage IA	T1a	NO	M0
Stage IB	T1b	NO	M0
Stage II	T2	NO	M0



AJCC CANCER STAGE: CORPUS UTERI	
CARCINOMAS	

Group	Т	N	М	
Stage III	T3	N0	M0	
Stage IIIA	T3a	N0	M0	
Stage IIIB	T3b	NO	M0	
Stage IIIC1	T1-T3	N1	M0	
Stage IIIC2	T1-T3	N2	M0	
Stage IVA	T4	Any N	M0	
Stage IVB	Any T	Any N	M1	

VAACCR

POP QUIZ

- Uterine biopsy: Endometrial adenocarcinoma
- CT scan pelvis/abdomen: Uterine mass, no lymphadenopathy, no organomegaly
- Hysterectomy, bilateral salpingooophorectomy, and pelvic node dissection: 3 cm endometrial adenocarcinoma, moderately differentiated, invading the pelvic sidewall; 0/6 pelvic nodes with metastasis; 0/6 para-aortic nodes with metastasis.

NAACCR

POP QUIZ

- What is the AJCC clinical stage?
- What is the AJCC pathologic stage?

LEIC	Ateg DMY(CON	DSARCOMA & ENDOMETRIAL	STROMAL
TNM	FIGO	Description	
ΤX		Primary tumor cannot be assessed	
TO		No evidence of primary tumor	
T1	1	Limited to uterus	

T1aIATumor 5 cm or less in greatest dimensionT1bIBTumor more than 5 cm

SAR	CON	1A	
TNM	FIGO	Description	
T2	II	Extends beyond the uterus within the pelvis	
T2a	IIA	Involves adnexa	
T2b	IIB	Involves other pelvic tissues	
T3	Ш	Infiltrates abdominal tissues	
T3a	IIIA	One site	
T3b	IIIB	More than one site	
T4	IVA	Invades bladder or rectum	

NO No regional lymph node metastasis	TNM	FIGO	Description
	NX		Regional lymph nodes cannot be assessed
N1 IIIC Degianal lumph pada matastasia	N0		No regional lymph node metastasis
Inc Regionallymphilode metastasis	N1	IIIC	Regional lymph node metastasis

M CATEGORY LEIOMYOSARCOM

LEIOMYOSARCOMA & ENDOMETRIAL STROMAL SARCOMA TNM FIGO Description

M0 No distant metastasis

M1 IVB Distant metastasis

POP QUIZ

- Uterine biopsy: Endometrial stromal sarcoma
- Abdominal/pelvic CT scan: Large uterine mass with no lymphadenopathy
- Chest x-ray: Normal
- Total hysterectomy with bilateral salpingooophorectomy: Enodmetrial stromal sarcoma of the myometrium involving left adnexa, left ovary, and omentum.

NAACCR

NAACCR

POP QUIZ

- What is the AJCC clinical stage?
- What is the AJCC pathologic stage?

T CATEGORY ADENOSARCOMA

TNM	FIGO	Description
TΧ		Primary tumor cannot be assessed
TO		No evidence of primary tumor
T1	I	Limited to uterus
T1a	IA	Limited to endometrium/endocervix
T1b	IB	Invades less than ½ of myometrium
T1c	IC	Invades more than ½ of myometrium

V	x	IL,	J.	n
			_	_

		GORY SARCOMA
TNM	FIGO	Description
T2	II	Extends beyond the uterus within the pelvis
T2a	IIA	Involves adnexa
T2b	IIB	Involves other pelvic tissues
T3	Ш	Involves abdominal tissues
T3a	IIIA	One site
T3b	IIIB	More than one site
T4	IV	Invades bladder or rectum

TNM	FIGO	Description
NX		Regional lymph nodes cannot be assessed
NO		No regional lymph node metastasis
N1	IIIC	Regional lymph node metastasis

VAACCR

Image: Matrix of the system Matrix of the system Image: Matrix of the system No Mo No No M1 IVB Distant metastasis

Group	T	N	М
Stage I	T1	NO	M0
Stage IA	T1a	NO	M0
Stage IB	T1b	NO	M0
Stage IC	T1c	NO	M0
Stage II	T2	NO	M0

Group	T	N	м
Stage IIIA	T3a	NO	M0
Stage IIIB	T3b	NO	M0
Stage IIIC	T1, T2, T3	N1	M0
Stage IVA	T4	Any N	M0
Stage IVB	Any T	Any N	M1



Summary Stage 2000 http://seer.cancer.gov/tools/ssm/

CORPUS UTERI

VAACCR

SUMMARY STAGE 2000: CORPUS UTERI

- 0 In situ
- Noninvasive; intraepithelial
- Pre-invasive
- FIGO Stage 0
- 1 Localized only
- Confined to endometrium (stroma); FIGO Stage IA
- Invasion of myometrium/serosa of corpus (tunica serosa); FIGO Stage IB; FIGO Stage IC
- · Localized NOS; FIGO Stage I not further specified

VAACCR

SUMMARY STAGE 2000: CORPUS UTERI

- Confined to endometrium
- In situ
- Tumor confined to columnar epithelium

Localized

 Tumor penetrated basement membrane and invaded stroma (lamina propria)

SUMMARY STAGE 2000: CORPUS UTERI

- · 2 Regional by direct extension only
- Extension to/involvement of:
- Cervix uteri NOS; FIGO Stage II NOS
- Endocervical glandular involvement only; FIGO Stage IIA
- Cervical stromal invasion; FIGO Stage IIB
- Extension or metastasis within true pelvis:
- Fallopian tube(s); ligament(s): broad, round, uterosacral; ovary(ies); parametrium; pelvic serosa; pelvic tunica serosa; ureter; vulva

VAACCR

SUMMARY STAGE 2000: CORPUS UTERI

- · 2 Regional by direct extension only
- Cancer cells in ascites
- Cancer cells in peritoneal washings
- FIGO Stage IIIA
- Extension or metastasis: Bladder NOS excluding mucosa; bladder wall; bowel wall NOS; rectum NOS excluding mucosa; vagina; pelvic walls
- FIGO Stage IIIB

NAACCR

SUMMARY STAGE 2000: CORPUS UTERI

- 3 Regional lymph node(s) involved only
- Aortic NOS: Lateral (lumbar), para-aortic, periaortic
- Iliac: Common, external, internal (hypogastric):
- obturator
- Paracervical
- Parametrial
- Pelvic NOS
- Sacral NOS: Lateral (laterosacral), middle (promontorial)
- (Gerota's node), presacral, uterosacral • FIGO Stage IIIC
- Regional lymph node(s) NOS

SUMMARY STAGE 2000: CORPUS UTERI

- 4 Regional by BOTH direct extension AND regional lymph node(s) involved • Codes (2) + (3)
- 5 Regional NOS FIGO Stage III NOS

NAACCR

VAACCR'

SUMMARY STAGE 2000: CORPUS UTERI

- 7 Distant site(s)/node(s) involved
- Distant lymph node(s):
- Inguinal NOS:
- · Deep, NOS;
- Node of Cloquet or Rosenmuller (highest deep inguinal)
- Superficial inguinal (femoral)
- Other distant lymph node(s)

SUMMARY STAGE 2000: CORPUS UTERI

- 7 Distant site(s)/node(s) involved
- Extension to:
- Bladder mucosa (excluding bullous edema)
- Bowel mucosa
- FIGO Stage IVA
- Further contiguous extension: Abdominal serosa (peritoneum); cul de sac (rectouterine pouch); sigmoid colon; small intestine
- Metastasis
- FIGO Stage IVB

POP QUIZ

- Uterine biopsy: Endometrial stromal sarcoma
- Abdominal/pelvic CT scan: Large uterine mass with no lymphadenopathy
- Chest x-ray: Normal
- · Total hysterectomy with bilateral salpingooophorectomy: Enodmetrial stromal sarcoma of the myometrium involving left adnexa, left ovary, and omentum.

NAACCR

POP QUIZ

- What is the code for Summary Stage 2000?
- a. 0 In situ
- b. 1 Localized only
- c. 2 Regional by direct extension only
- c. 2 Regional by direct extension only
 d. 3 Regional lymph node(s) involved only
 e. 4 Regional by BOTH direct extension AND regional lymph node(s) involved
 f. 5 Regional NOS
 7 Direct site() (node (s) involved

- g. 7 Distant site(s)/node(s) involved h. 9 Unknown if extension or metastasis

VAACCR'

Collaborative Stage Data Collection System (CS) V0205

CORPUS UTERI

CORPUS UTERI SCHEMAS CS V0205

- CorpusAdenosarcoma*
 ICD-O-3 Histology Code: 8933
- CorpusCarcinoma*
- ICD-O-3 Histology Code Ranges: 8000-8790, 8950, 8951, 8980-8981,9700-9701
- CorpusSarcoma*
 ICD-O-3 Histology Code Ranges: 8800-8932,8934-8941,8959-8974, 8982-9136,9141-9582
- *ICD-O-3 Topography Codes: C54.0, C54.1, C54.2, C54.3, <u>C54.8, C54.9, C55.9</u>

VAACCR

SSF1 FIGO STAGE

- Code as documented in medical record
 Do not try to code from T, N, M values
- Assign code 987 for carcinoma in situ
- CS Extension = 000
- FIGO Stage does not include Stage 0 (in situ) for corpus uteri
- Assign code 999 if FIGO stage is unknown or not documented

VAACCR

SSF2 PERITONEAL CYTOLOGY

- Code results of cytology from peritoneal or pelvic washings
- Negative, positive, or suspicious cytology
- Exam performed on
- AscitesSaline solution flooded in the pelvic & peritoneal cavities

NUMBER OF NODES POSITIVE & EXAMINED

- SSF3: Number of Positive Pelvic Nodes
- SSF4: Number of Examined Pelvic Nodes
- SSF5: Number of Positive Para-aortic Nodes
- SSF6: Number of Examined Para-aortic Nodes

NAACCR'




NAACCR

DIAGNOSTIC/STAGING PROCEDURES

Cervix

- PAP Smear
 Not as effective with
- Not as effective with adenocarcinoma
- Biopsy
- ColposcopyCone biopsy
- Cone blops
 Imaging
- MRĬ • CT
- CT • PET-CT






TREATMENT-CERVIX


- IA1
- Fertility sparing
- Cone biopsy with margins negative and negative LVSI

- Cone biopsy with positive margins or positive LVSI
 Cone biopsy with positive margins or positive LVSI
 Radical trachelectomy and pelvic lymph node dissection
 May also have para-aortic lymph node dissection

- Ivray also have para-aortic lymph node dissection
 Non-fertility sparing

 Negative LVSI-Simple hysterectomy
 Positive LVSI-modified radical hysterectomy with pelvic lymph node dissection





TREATMENT CERVIX

• IA2

- Fertility sparing
- Radical trachelectomy and pelvic lymph node dissection
 May also be done for Stage IB1 if tumor is less than 2cm
- Non-fertility sparing
- Radical hysterectomy and bilateral pelvic lymph node dissection with (or without) para-aortic lymph node sampling
- Pelvic Radiation with brachytherapy for medically inoperable patients or those that refuse surgery.

NAACCR

TREATMENT-CERVIX


- IB and IIA
- Non-fertility sparing
- IB1 and 2A1-Radical hysterectomy and bilateral pelvic lymph node dissections with (or without) para aortic lymph node sampling
- Definitive radiation and brachytherapy +/- concurrent cisplatin based chemotherapy
- · IB2 and IIA2-Concurrent chemoradiation
- Definitive pelvic radiation
- Concurrent cisplatin based chemotherapy and brachytherapy

NAACCR

NAACCR 2014-2015 Webinar Series

SENTINEL LYMPH NODE MAPPING

- A dye with a radiotracer is injected around the lesion
- The first nodes the dye travels to are the sentinel lymph nodes



NAACCR

VAACCR'

EXTERNAL BEAM RADIATION THERAPY (EBRT) • The volume of EBRT should cover the gross disease, parametria, uterosacral ligaments, sufficient vaginal margin, presacral nodes, other nodal volumes at risk



NAACCR 2014-2015 Webinar Series

TREATMENT-CERVIX


- Advanced disease-Stage IIB through IVA Radiation, cisplatin based chemotherapy and
- brachytherapy Metastatic disease
- Chemotherapy and radiation

NAACCR

TREATMENT-ENDOMETRIUM

- Confined to the uterus Total hysterectomy (with or without lymph node dissection)
- Cervical involvement
 Radical hysterectomy
 Neoadjuvant radiation
- Extrauterine disease Hysterectomy and debulking
 EBRT plus or minus vaginal brachytherapy
 Chemotherapy





TREATMENT-ENDOMETRIUM

- Total
- hysterectomy/bilateral salpingo-oopherectomy Pelvic lymph node dissection


- Para-aortic lymph node dissection
- · To the level of the renal vessels
- Peritoneal lavage



SYSTEMIC THERAPY · Chemotherapy

- Cisplatin/doxorubicin plus or minus paclitaxel
- Hormone therapy
 Continuous progestin base therapy for state IA patients
 Fertility sparing
 Patient must meet specific criteria
 Requires frequent monitoring
 Hysterectomy should be completed after childbearing is complete

VAACCR



COMING UP...

- Abstracting & Coding Boot Camp • 3/5/15
- Collecting Cancer Data: Stomach & Esophagus

• 4/2/15



CE CERTIFICATE QUIZ/SURVEY

Phrase

Link
 <u>http://www.surveygizmo.com/s3/1986035/Uterus-2015</u>